Abstract: An objective of the present invention is to provide an external preparation for concealing roughness that is easy to spread when applied, while also having effects of concealing roughness such as fine wrinkles. The external preparation for concealing roughness of the present invention comprises (a) 1% to 15% by mass of a wax; and (b) 4% to 25% by mass of a non-spherical powder; and has a viscosity of 50,000 to 150,000 mPa·s.

Abstract: A composition for skin whitening and wrinkle improvement includes an adventitious root extract of Centella asiatica as an effective ingredient. The adventitious root extract of Centella asiatica has an excellent anti-inflammation and antioxidant activity without any cytotoxicity and also has an excellent effect of inhibiting the melanin pigmentation and matrix metalloprotease and enhancing the production of procollagen as a precursor of collagen. Accordingly, it can be advantageously used as a cosmetic, a preparation for external application on skin, or the like for skin whitening and wrinkle improvement.

Abstract: The present invention discloses an advance enhanced stability, enhanced solubility and an enhanced photoprotective effect by proposing an improved process by presenting a technique where the skin care products inform of serum is presented. The proposed method provides compositions with necessary ingredients including but not limited to Organic rose hip oil, organic wheat germ, organic Gotu kola, organic onion seed oil and vitamins such as A, B3, B5 and E containing cosmetics used to address age, wrinkles, stretch marks, dark spots, spider veins, razor bumps, ingrown hair, loose and soggy skin and environmental induced damage.

Abstract: Disclosed is a method for eliminating odors including administering a deodorant composition containing an Opuntia ficus (prickly pear) extract or a fraction thereof as an active ingredient. The deodorant composition, which further contains a persimmon extract or a fraction thereof, a persimmon juice, or a green tea extract or a fraction thereof, is useful as a deodorizer for removing or reducing ammonia and trimethylamine.

Abstract: The present invention relates generally to methods of use and compositions for enhancing skin hydration in a person, attracting and binding moisture in the air to the skin's outer layers, transporting surface moisture below the skin's stratum corneum, increasing skin moisture content, plumping and tightening the skin, protecting the skin from moisture loss to the environment, supporting optimal skin barrier function, and/or stimulating production of the skin's own Natural Moisturizing Factor. The composition includes a combination of the Verbena officinalis extract, hydrolyzed sodium hyaluronate, and ceramide.

Abstract: There is provided a formulation for skin rejuvenation comprising lyophilised umbilical cord plasma comprising at least one active chemokine, at least one growth factor and at least one cytokine; a transdermal carrier; and a liposomal base, wherein at least a portion of the lyophilised umbilical cord plasma and transdermal carrier are contained within liposomes of the liposomal base. There is also provided a dosage form for skin rejuvenation comprising 1-5% (w/w) lyophilised umbilical cord plasma comprising at least one active chemokine, at least one growth factor and at least one cytokine; 85-95% (w/w) polyethylene glycol; and 0.1-2% (w/w) gum acacia.

Abstract: A method for reducing the appearance of a skin pore in skin of a subject in need thereof is disclosed. The method can include topically applying to the skin pore a composition comprising effective amount of Albizia julibrissin bark extract, and hydrolyzed soy flour, wherein topical application of the composition reduces the appearance of the size of the skin pore.

Abstract: A method of treating skin with a composition is disclosed. The method can include topically applying an effective amount of a composition to skin in need thereof, wherein the composition comprises an aqueous extract of plankton comprising an exopolysacchride synthesized by Vibo alginolyticus, an aqueous extract of Phragmites communis, an aqueous extract of Poria cocos, and an aqueous extract of Cucurbita pepo (pumpkin) seed.

Abstract: A composition includes a salt; a polymer; and an antioxidant. A dispenser includes a flexible container having a closed end and an opposed open end; an osmotically-effective solute composition encapsulating at least a portion of the container, the solute composition including antioxidant in an amount of at least 0.5 wt %, based on weight of the solute composition; a semipermeable membrane encapsulating the osmotically-effective solute composition; a cap having a sealing surface adapted for sealing engagement with the open end of the container; and a port extending from an interior of the container and through the cap. Also disclosed are methods of making and using the composition and osmotic pumps.

Abstract: The task of initiating a 20 minutes cycle of skin temperature regulation through Gibs Free Energy and sets in the breaking down of the nutrients for skin absorption by taking advantage of assimilating the mechanism of sebaceous gland's function in relation to the growth and maintenance of hair with radish, garlic, and vitamin E oil.

Abstract: Embodiments of the application are directed toward a liquid topical sinus therapy for a patient, comprising a medicated formulation including at least one medication, and a device for delivering the medicated formulation to the patient's nostrils, nasal passages, or sinuses. The medicated formulation may include drugs selected from the group consisting of corticosteroids, antibiotics, antifungals, antihistamines as well as herbal and alternative medications. Dosage forms include powders, tablets and gels which facilitate clinical testing and enable patient compliance.

Abstract: Described herein are methods and compositions for reducing transmission of Plasmodium to a female mosquito. Aspects of the invention relate to contacting to a mosquito with a Plasmodium transmission blocking compound. Another aspect of the invention relates to a surface coated with a Plasmodium transmission blocking compound.

Abstract: An ophthalmic pharmaceutical composition containing an azole compound, a method for preparing the same, as well as a use of the pharmaceutical composition in the preparation of an ophthalmic preparation for preventing and treating ophthalmic diseases. The ophthalmic preparation contains the azole compound at a concentration of 0.005-400 ?M.

Abstract: An oral sanitizer composition with immune support for viral, bacterial and COVID-19 prevention. The oral sanitizer composition formulated into a mouthwash, a mouth rinse, a mouth strip a throat lozenge, a mouth spray, a throat spray or a nasal spray. The oral sanitizer composition being formulated with alcohol and without alcohol.

Abstract: Compositions and methods of use related to formulations comprising anesthetics are generally described. Some embodiments are directed to compositions comprising a plurality of micelles and/or particles, and an anesthetic contained internally. These can be used to control and/or prolong the duration of IVRA while reducing the risk of systemic toxicity commonly due to administering anesthetics. The control and/or prolonged duration of IVRA may be due, at least in part, to the attachment of the sufficiently small micelles and/or particles to a biointerface (e.g., blood vessel surface) where the composition has been administered. Conventional IVRA methods commonly do not utilize potent and long-acting anesthetics (e.g., bupivacaine) due to the risks of cardiac toxicity. The compositions and methods described herein, however, provide a pathway for increased safety and efficiency of the use of such anesthetics, in certain embodiments. Resultantly, the performance (e.g.

Abstract: A method for encapsulating active ingredients in liposomes having an active ingredient solution encapsulated with a bilayer composed of two monomolecular layers of a first and a second amphiphilic compound, wherein the method comprises: (a) providing the active ingredient solution; (b) providing an emulsion by emulsifying the active ingredient solution in a first liquid in the presence of the first amphiphilic compound; (c) providing a mixture with a liquid phase with the second amphiphilic compound; (d) contacting the first emulsion with the mixture to form a phase boundary; and (e) centrifuging the first emulsion and the mixture wherein, on passage of the phase boundary, the second amphiphilic compound enriched there is added onto the monomolecular inner layer of the pre-liposomes to form a monomolecular outer layer, in order to create the bilayer.

Abstract: The disclosure provides compositions and products configured for oral use. For example, a composition is provided that includes a foam containing a lipid and an active agent and/or a flavorant, and a carrier, wherein the foam is adsorbed onto the carrier. Such a foam can be incorporated, e.g., within lozenges and/or pouched oral products. The disclosure further provides an oral product (e.g., a lozenge and/or pouched oral product) including an encapsulated agent, wherein the encapsulated agent is a porous bead with an exterior portion and an interior portion containing a lipid and an active agent and/or a flavorant.

Abstract: The present invention relates to a melt composite comprising one or more curcuminoids and a carrier selected from rice bran extract, mannitol, maltodextrin and mixtures thereof. The invention also provides a process for preparation of the melt composite, wherein the mixture of curcuminoids, rice bran extract, mannitol, maltodextrin and mixture thereof may be subjected to controlled conditions of heating and granulation. The melt composite may also be optionally comprised of one more excipient suitable for use for human consumption. Curcuminoid composites can be formulated in suitable solid, liquid or semisolid compositions. Curcuminoid composites and the compositions thereof, exhibit rapid dissolution and enhanced bioavailability.

Abstract: An object of the present invention is to provide a solid drug formulation having excellent stability. The solution according to the present invention is a solid drug formulation containing: a compound having formula (I): (i) D-mannitol; (ii) carmellose calcium; (iii) citric acid hydrate or the like; and (iv) ?-tocopherol.

Abstract: At present, the most prevalent pharmaceutical dosage forms, the oral immediate-release tablets and capsules, are porous solids of compacted drug and excipient powders. Upon ingestion, physiological fluid percolates the open pores, and the dosage form disintegrates and the drug dissolves. Because the pores in the compacted solids are not well connected, however, fluid percolation generally is not uniform, and the drug release rate is difficult to predict and control. To overcome such limitations, therefore, herein a structured solid dosage form is disclosed. The structured solid dosage form comprises a structural assembly of one or more repeatably arranged, extruded structural elements. The elements comprise segments separated and spaced from adjoining segments by free spacings defining one or more substantially interconnected free spaces, or channels, in the dosage form through which a physiological fluid may percolate.

Abstract: Fast-acting, bioavailable liquid softgel fill compositions comprising (a1) a pain reliever/fever reducer; (a2) a diuretic; (a3) an antihistamine; (b1) a pharmaceutically acceptable polyalkylene glycol; (b2) a pharmaceutically acceptable alkylene glycol; (c1) a pharmaceutically acceptable polymeric solubilizer; (c2) water; and (d) an antioxidant/preservative are disclosed, where the liquid softgel fill composition does not crystallize or otherwise deposit any of the active ingredients. Also disclosed are methods for the preparation of such fill compositions, and softgel capsules containing the bioavailable liquid fill composition.

Abstract: The invention relates to a product, method of use, and/or method of preparing a capsule or capsular like product that comprises hydrophilic fluid-absorbing materials that bind, entrap, and/or absorb large quantities of fluid. The capsules or capsular like product may be capable of diverting the mode of fluid and waste elimination from the renal route to the gastrointestinal route.

Abstract: The embodiments herein provide a pharmaceutical composition for use in a combination with cannabinoids that includes a primary essential oil, and a secondary essential oil to support the human endocannabinoid system. The primary essential oil replenishes a plurality of first micronutrients lost during the processing of cannabis. The primary essential oil contains a first therapeutically effective amount of crude cannabis essential oil. The secondary essential oil replenishes a plurality of second micronutrients lost during the processing of cannabis. The secondary essential oil contains a second therapeutically effective amount of crude cannabis essential oil. The primary essential oil and the secondary essential oil are in a liquid form. The liquid form of the primary essential oil and the secondary essential oil are respectively transformed into a powder form by performing a microencapsulation process.

Abstract: One aspect of the disclosure describes a lipid conjugated cationic molecule. Other aspects of the disclosure describes nanoparticle delivery systems and methods of making the systems are disclosed. An embodiment of the nanoparticle delivery system has sustained gene delivery properties, the nanoparticle delivery system can be synthesized using biodegradable and biocompatible polymers via self-assembly. The nanoparticle delivery system comprises a plurality of nanoparticle depots, each of which has a particle-in-particle structure, and is composed of a polymeric nanoparticle, which encapsulates cationic molecule/nucleic acid complexes, facilitating enhanced retention and prolonged release of the gene payload. The polymeric nanoparticle comprises a shell, and a nanocomplex of the cationic molecule and a polynucleotide, the nanocomplexes are distributed within the shell and/or embedded in the shell. Another embodiment of the nanoparticle delivery system has one or more nanocomplexes.

Abstract: Compositions of nanolipid carrier molecules comprising PEG molecules and solid and liquid lipids wherein the PEG has a molecular weight of between about 1000 and 5000 are described. Methods of administering nanolipid carrier molecules are also described. Also described is a method for treating fungal ocular infections by topical ocular administration of nanolipid carrier molecules comprising PEG molecules and solid and liquid lipids wherein the PEG has a molecular weight of between about 1000 and 5000.

Abstract: The present invention relates to compositions and methods to treat and/or prevent biofilms and biofilm related diseases. The invention comprises a nanoparticle carrier (NPC) and at least one therapeutic agent therein. The NPC binds within biofilm and to surfaces at risk for biofilm formation and accumulation while providing local, sustained, enhanced and controlled delivery of the therapeutic agent, when triggered for release. In one embodiment, the NPC comprises pH-responsive elements that allows for specific delivery of the therapeutic agent when the local environment dictates that the agent should be delivered precisely when it is most needed.

Abstract: Nanoparticle compositions for delivery of nucleic acids to subjects including modified dendrimers comprising cores, one or more of homogeneous or heterogeneous intermediate and terminal layers, and therapeutic or immunogenic nucleic acid agents enclosed within nanop article compositions are described. Methods for treating or preventing diseases or conditions in a subject by administering the nanoparticle compositions that provide immune responses and synergistic therapeutic or preventive effects are provided.

Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.

Abstract: The present invention relates to a patch comprising a high content of rivastigmine per unit area, which can be continuously administered for a long time. The rivastigmine patch according to the present invention is capable of continuous release of rivastigmine for a long period of time, preferably 3 days, more preferably 4 days or more after attachment, and has excellent physical and chemical stability.

Abstract: Methods of treating a subject having a gram negative bacterial infection by administering a cannabinoid such as 2-AG,CBD, the MgI inhibitor JZL184, or arachidonic acid to the subject are provided. Methods of prophylactically treating a subject at risk of developing a gram negative bacterial infection and for reducing the bacterial virulence in an infected subject are also provided.

Abstract: A method of inducing anesthesia in a subject is provided. In some embodiments, the method provides administering to the subject via the respiratory system or via injection, an effective amount of a compound or a mixture of compounds selected from the group consisting of methyl-ethyl ethers, methyl-isopropyl ethers, and methyl-propyl ethers.

Abstract: Provided herein are methods for treating cancer comprising administering to a subject in need thereof an adamantane derivative, or a pharmaceutically acceptable salt thereof, such as rimantadine or amantadine. In some embodiments, the adamantane derivative is PEGylated.

Abstract: The present invention provides a new drug that can accelerate glucose consumption. The glucose consumption accelerator of the present invention includes: at least one selected from the group consisting of 2-amino-1-cyclohexylethanol, 1-amino-2-propanol, 1,3-bis[tris(hydroxymethyl)methylamino]propane, N-cyclohexylethanolamine, diethanolamine, diethylamine, dipropylamine, morpholine, propylamine, triethanolamine, triethylamine, and trishydroxymethylaminomethane.

Abstract: Methods and compositions utilizing 2-aminoindan derivatives collectively represented by Formula I as described and defined in the specification for regulating binge behavior, particularly binge drinking, are disclosed.

Abstract: Methods and compositions utilizing 2-aminoindan derivatives collectively represented by Formula I as described and defined in the specification for regulating binge behavior, particularly binge drinking, are disclosed.

Abstract: Methods and compositions utilizing 2-aminoindan derivatives collectively represented by Formula I as described and defined in the specification for regulating binge behavior, particularly binge drinking, are disclosed.

Abstract: 5-HT receptor agonists are useful in the treatment of a variety of diseases. Provided herein are methods of reducing the incidence and/or severity of seizures in a human patient using a 5-HT receptor agonist, such as, for example, a 5-HT4 agonist (e.g., fenfluramine). Methods of treating epilepsy or epileptic encephalopathy, and/or reducing, ameliorating or eliminating incidence of SUDEP in a subject diagnosed with epilepsy by administering a 5-HT4 agonist (e.g., fenfluramine) to a subject in need thereof are provided. Pharmaceutical compositions for use in practicing the subject methods are also provided.

Abstract: Provided herein are compositions and methods to treat or prevent neurodegeneration in a mammal, inhibit microglial activation in the CNS of a mammal, promote survival of CNS neurons in a mammal, prevent or reduce the rate of demyelination and/or neuronal injury in a mammal, promote remyelination in a mammal and/or treat or prevent or decrease oxidative stress in a mammal.

Abstract: Disclosed herein are methods of treating a CDK4/6 inhibitor resistant estrogen receptor alpha-positive cancer in a subject having either a wild-type estrogen receptor alpha and/or a mutant estrogen receptor alpha, the method comprising administering to the subject a therapeutically effective amount of elacestrant, or a pharmaceutically acceptable salt or solvate thereof, wherein the mutant estrogen receptor alpha comprises one or more mutations selected from the group consisting of D538G, Y537X1, L536X2, P535H, V534E, S463P, V392I, E380Q and combinations thereof, wherein: X1 is S, N, or C; and X2 is R or Q. In some embodiments, the CDK4/6 inhibitor resistant estrogen receptor alpha-positive cancer is selected from the group consisting of breast cancer, uterine cancer, ovarian cancer, and pituitary cancer.

Abstract: This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.

Abstract: Phenylephrine particles suitable for solid, semi solid or liquid dosage forms are disclosed.

Abstract: The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.

Abstract: An object of the present invention is to provide a drug containing, as an active ingredient, a low-molecular-weight compound that ameliorates obesity-related metabolic diseases, for example, exhibits anti-obesity action without reduction of food intake through binding to Helz2 to lower its action, on the basis of the fact that Helz2 is intensely expressed in the liver both in humans and mice, and expression levels are significantly increased in the human liver with NAFLD, as an obesity-related metabolic disease, and in fatty liver in obese mice. The present invention provides an ameliorating agent for an obesity-related metabolic disease, in particular, an ameliorating agent for fatty liver, the ameliorating agent characterized by containing guanabenz or a salt of guanabenz as an active ingredient.

Abstract: A method for stabilizing a sanshool compound is provided. The method for stabilizing a sanshool compound comprises a mixing step in which the sanshool compound is mixed with an antioxidant in a liquid, the liquid comprising water and/or a water-soluble organic solvent and the mixing step being conducted under the conditions of a pH of 6 or higher.

Abstract: Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof.

Abstract: Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof.

Abstract: The present invention relates generally to new and improved compositions and methods for producing reliable relief from irritation or itching of the skin of the scalp.

Abstract: Methods of treating of interstitial lung disease, reducing pulmonary function decline in a subject with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in a subject suffering from ILD are provided, wherein the methods include administration of treprostinil.

Abstract: A method for amelioriation of, or prophylaxis against, a viral infection comprising administering to a patient in need of treatment a therapeutically effective amount of 5 aminolevulinic acid, optionally with at least one of cucumarin nano, zinc, vitamin C and methylene blue, and compositions thereof. Such compositions may be used for the treatment of coronavirus infections, including the SARS-CoV-2 virus, and/or rhinoviruses.

Abstract: The invention relates to an active ingredient consisting of several polylysine compounds, said polylysine compounds consisting of at least one small molecule conjugated to a polylysine, said active ingredient comprising at least the following polylysine compounds: Coenzyme Q10-Polylysine Retinoic Acid-Polylysine Cysteine-Polylysine Taurine-Polylysine Glutathione-Polylysine, for use in humans or animals, to prevent strokes and/or treat the inflammatory phase following a stroke.